Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Status:
Completed
Trial end date:
2019-06-06
Target enrollment:
Participant gender:
Summary
To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the
treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given
intra-arterially after osmotic blood-brain-barrier disruption.